可絡暢膜衣錠20毫克

国家: 台湾

语言: 中文

来源: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

有效成分:

BETAXOLOL HCL

可用日期:

賽諾菲股份有限公司 台北市信義區松仁路3號7樓 (97168356)

ATC代码:

C07AB05

药物剂型:

膜衣錠

组成:

BETAXOLOL HCL (1216002410) MG

每包单位数:

盒裝

类:

製　劑

处方类型:

須由醫師處方使用

厂商:

SANOFI WINTHROP INDUSTRIE 30-36 AVENUE GUSTAVE EIFFEL 37000 TOURS FRANCE FR

治疗领域:

betaxolol

疗效迹象:

動脈性高血壓、穩定型狹心症。

產品總結:

註銷日期: 2021/04/09; 註銷理由: 自請註銷; 有效日期: 2025/05/11; 英文品名: KERLONE 20MG, SCORED FILM-COATED TABLET

授权状态:

已註銷

授权日期:

2020-05-07

资料单张

1
KERLONE 20MG
Betaxolol
Scored coated tablets
COMPOSITION
Betaxolol
hydrochloride................................................20mg
Excipient: Lactose, Carboxymethylamidon, Microcrystalline cellulose,
Anhydrous colloidal silica, Magnesium stearate, Hypromellose, Macrogol
400 and
Titanium dioxide。
PROPERTIES
KERLONE is a cardioselective beta-blocker with a long duration of
action.
THERAPEUTIC INDICATIONS
- Arterial hypertension;
- Prevention of attacks of angina pectoris occurring during exercise.
CONTRA-INDICATIONS
DO NOT USE this drug in the following cases:
- combination with sultopride;
- Cardiac insufficiency not controlled by treatment;
- Cardiogenic shock
- Bradycardia (less than 45-50 beats per minute);
- Prinzmetal variant of angina (in pure forms and with monotherapy);
- sinoatrial dysfunction (including sinoatrial block);
- Hypotension;
- Serious disorders of the peripheral arteries, Raynaud’s
phenomenon;
- Known hypersensitivity to betaxolol;
- history of anaphylactic reactions;
- metabolic acidosis;
- Treatment with floctafenine;
- Certain severe forms of asthma and obstructive bronchopneumopathies;
- Untreated phaeochromocytoma.
If in doubt, it is essential to request the opinion of your doctor or
pharmacist.
WARNINGS
NEVER INTERRUPT THE TREATMENT ABRUPTLY. If discontinuation of the
treatment is necessary, the dosage must be reduced gradually; CONSULT
YOUR DOCTOR.
Sportsmen should note that this product contains an active principle
which may induce a positive reaction in tests conducted during
anti-doping controls.
PRECAUTIONS FOR USE
In case of discontinuation of the treatment, the dosage must be
reduced over one-two weeks, if necessary starting the substitutive
therapy at the same time.
Use with caution in case of:
- Mild forms of asthma and chronic obstructive bronchopneumopathies.
In the event of an attack during the treatment, beta-mimetie
bronchodilatators may be used.
- Controlled cardiac insufficiency, non-severe bradycardia (more the
50 beats perminute), non-severe disturbances of ca